Dragon Pharmaceuticals (DRUG) Konkurrenz für Amgen!! - 500 Beiträge pro Seite

[RogerThat]

Dragon Acquires Rights to Novel Slow Release EPO Formulation

Dragon Pharmaceuticals Inc. (OTC BB: DRUG - news) is pleased to announce that it has entered into an agreement related to a novel, slow-release formulation for Erythropoietin (EPO) with Transworld Pharmaceuticals Corp. of Portugal and Renapharm AB of Sweden. EPO has been the most effective drug for the treatment of severe anemia since its introduction in 1989 and is ranked by IMS Health as the world`s fastest growing drug by annual sales, with estimated worldwide sales of $4.8 billion in 2000.

The agreement provides Dragon with sole worldwide manufacturing rights as well as exclusive marketing rights to Asia, including China, Japan, Korea, and SE Asia. Transworld Pharmaceuticals, a leading international distributor of blood related products and biotechnology drugs, will have exclusive marketing rights to all markets outside Asia.

``We are extremely pleased to have completed this agreement,`` said Dr. Longbin Liu, President and Chief Executive Officer of Dragon. ``We are one of only two companies worldwide developing a sustained release formulation for EPO. This agreement is a key development which will support our goal of developing a leading competitive position in the worldwide EPO market by offering premium quality generic product at significantly lower prices than branded product.``

A pilot clinical trial conducted in 101 patients at the University Hospital, Uppsala University of Sweden, assessed the monthly administration of EPO in this slow release formulation compared to the four times per week administration of conventional EPO. The total dose of each form of EPO was identical. The results of the study showed that monthly administration of the slow release formulation had the same therapeutic effect as four times per week conventional EPO with the added advantage of requiring less frequent injections.

According to the agreement, each partner will participate in the final development of this formulation. Dr. Bo Danielson MD PhD, Managing Director of Renapharm and developer of the slow-release formulation, will serve as lead clinical and technical advisor to the project. Dr. Danielson is recognized as a world expert on EPO, having participated in over 75 published clinical studies involving EPO.

The potential market for slow-release EPO is estimated at US$5 billion per year, with application in the treatment of anemia in patients with kidney failure and cancer patients undergoing chemotherapy.

Prior to the 2004 expiry of the EPO gene patent, generic forms of EPO may only be sold in developing world markets outside of North America, the European Union, Japan, Australia, and New Zealand. Given that Dragon`s slow release formulation includes the Company`s generic form of EPO, initial sales will focus on those markets not protected by the EPO gene patent. After 2004, Dragon`s new formulation would not be restricted by any existing patents and would be eligible for marketing throughout the world.

About Dragon Pharmaceuticals

Dragon Pharmaceuticals Inc. is an international biopharmaceutical corporation engaged in the discovery, development and commercialization of genetically engineered human proteins for therapeutic use. Based on its proprietary protein expression technology, Dragon has become one of the world`s lowest cost producers of Erythropoietin (EPO) - a breakthrough drug that has revolutionized the treatment of anemia. Dragon is now applying its platform technology to the development of other generic therapeutic proteins as well as to novel and patentable protein drugs.

Cautionary Statement for Purposes of the ``Safe Harbor`` Provisions of the Private Securities Litigation Reform Act of 1995: All statements, other than historical facts, included in the foregoing press release regarding the Company`s agreement to develop a slow-release formulation of EPO and its business strategy are forward-looking statements. Such forward-looking statements include, but are not limited to, the Company`s ability to develop, manufacture and market, a slow-release formulation of EPO, and the potential market for a slow-release EPO. These statements are based on management`s beliefs and assumptions, and on information currently available to management. Forward-looking statements are not guarantees of future performance. They involve risk, uncertainties and assumptions including risks discussed under ``Risks Associated With Dragon Pharmaceuticals`` in the Company`s annual report on Form 10-K, SEC File No.: 0-27937, all of which are incorporated herein by reference. The Company does not undertake the obligation to publicly revise these forward-looking statements to reflect subsequent events or circumstances.


--------------------------------------------------------------------------------
Contact:

DRAGON PHARMACEUTICALS
Rita Jervis, 604/669-8817
Fax: [phone]

[RogerThat]

Ich empfehle allen die Internetseite von Dragon einmal anzuschauen:
www.dragonpharmaceuticals.com

[RogerThat]

Der Aktienkurs von DRUG legt einen unglaublichen Tag hin. Mit über 400`000 gehandelten Aktien steigt der Kurs um 17% auf $3.10.

DRUG ist meiner Meinung nach auf dem besten Weg ein sehr erfolgreiches BioTech-Unternehmen zu werden!

[Javaboy]

Hallo RogerThat!

DRUG sieht wirklich sehr gut aus. Die heutige Börseneröffnung war ja wieder super! Nach 10 Minuten schon wieder 8 % im Plus.

Kennst Du die Internetseite von Brauer Marconi? Die erwähnen DRUG auf dieser Seite!
http://www.brauermarconi.com

[Kelbi]

Korrektur, +27 % bei sehr hohen Umsätzen, jetzt schon über 600000.

[RogerThat]

Hi Kelbi!

Die Umsätze scheinen zu explodieren! Bereits über 700`000 Aktien gehandelt. Es sieht sehr gut aus.

RogerThat

[RogerThat]

WOW! Schon wieder 5% im Plus bei der Eröffnung. Kurs inzwischen bei knapp über $4.00. Es sieht weiterhin sehr gut aus!

[RogerThat]

Wow! DRUG hat ein Auftrag von $1,8 Mio erhalten. Im ganzen letzten Jahr haben sie $3 Mio. erwirtschaftet.

Dragon Receives $1.8 Million Additional EPO Order From Itaca Laboratorios
VANCOUVER, British Columbia--(BW HealthWire)--July 11, 2001--Dragon Pharmaceuticals (OTCBB: DRUG - news) is pleased to announce that it`s Brazilian partner, Itaca Laboratorios Ltda., has placed an additional order for $1.8 million worth of Dragon`s EPO for delivery in 4Q 2001.

This is in addition to a previous order for $1.4 million placed in January of this year, and brings Dragon Pharmaceuticals` total orders from Itaca to $3.2 million for 2001. Additionally, Itaca has spun-off a new business, Biolotus, which will handle Dragon`s current and pipeline products, as well as collaborate with Dragon on new drug development.

Biolotus, headed by CEO Dr. Joao Transmontano, is in the process of aggressively seeking registration for Dragon`s EPO throughout the remainder of Latin America. This region represents a largely under-served market for biotech products, and only a few countries, such as Brazil and Mexico, have universal healthcare systems that offer reimbursement for EPO therapy. In the poorest countries of the region, such as Nicaragua, Peru, and Ecuador, only a fraction of eligible patients can afford treatment with EPO and other biotech drugs.

According to Dragon`s CEO and President, Dr. Longbin Liu, ``We appreciate the chance that Biolotus has given us to bring a high-quality and truly low-cost EPO to the patient populations in the most need.`` Making EPO ``is not exactly rocket science,`` quipped Dr. Liu, ``but knowing how to make it right and make it so average people can afford it is as close as it gets - and by showing we can do it, we validate our business model.``

About Dragon Pharmaceuticals Inc.

Dragon Pharmaceuticals Inc. is an international biopharmaceutical corporation engaged in the discovery, development and commercialization of genetically engineered human proteins for therapeutic use. Based on its proprietary protein expression technology, Dragon has become one of the world`s lowest cost producers of Erythropoietin (EPO) - a breakthrough drug that has revolutionized the treatment of anemia. Dragon is now applying its platform technology to the development of other generic therapeutic proteins as well as to novel protein drugs with worldwide patent potential.

The foregoing includes forward looking statements and readers should not place undue reliance on such forward looking statements, which only reflect the view of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward-looking statements to reflect subsequent events or circumstances.

For further information, please contact Rita Jervis, VP Corporate Development at [phone] or Facsimile [phone] or visit our web site at www.dragonbiotech.com.


--------------------------------------------------------------------------------
Contact:

Dragon Pharmaceuticals Inc.
Rita Jervis, 604/669-8817
Fax: [phone]